Thromb Haemost 2011; 105(02): 207-208
DOI: 10.1160/TH10-12-0818
Editorial Focus
Schattauer GmbH

Aging in Haemophilia: Getting to the heart of the matter

Margaret V. Ragni
1   Department of Medicine, Division Hematology/Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
› Author Affiliations
Further Information

Publication History

Received: 23 December 2010

Accepted: 23 January 2010

Publication Date:
25 November 2017 (online)

 

 
  • References

  • 1 Plug I, van der Bom JG, Peters M. et al. Mortality and causes of death in patients with haemophilia. 1992–2001: a prospective cohort study. J Thromb Haemost 2006; 4: 510-516.
  • 2 Population Division, DESA, United Nations World Population Ageing 1950–2050: Executive Summary. Available at http://www.un.org/esa/population/publications/worldageing19502050/pdf/62/executivesummary_english.pdf Accessed November 28, 2010.
  • 3 Triemstra M, Rosendaal F, Smit C. et al. Mortality in patients with haemophilia: changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995; 123: 823-827.
  • 4 Darby SC, Kan SW, Spooner RJ. et al. Mortality rates, life expectancy, and causes of death in people with haemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-825.
  • 5 Marmur JD, Thiruvikraman SV, Fyfe BS. et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-1232.
  • 6 Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: Biology. Lancet 1999; 3535: S115-119.
  • 7 Park YM, Febbraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest 2009; 119: 136-145.
  • 8 Khalloou-Laschet J, Calgiuri E, Tupin E. et al. Role for the intrinsic coagulation pathway in atherogenesis assessed in haemophilic apolipoprotein E knockout mice. Arteriscler Thromb Vasc Biol 2005; 25: 123-126.
  • 9 Nichols TC, Bellinger DA, Reddick RL. et al. The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and haemophilia A. Blood 1993; 81: 2644-2651.
  • 10 Foley CM, Nichols LA, Jeoung K. et al. Atherosclerosis and cardiovascular mortality in haemophilia. J Thromb Haemost 2010; 8: 208-211.
  • 11 Ragni MV, Moore CG. Atherosclerotic heart disease in haemophilia A: Prevalence and risk factors. Haemophilia. 2011 in press.
  • 12 Kulkarni R, Soucie JM, Evatt BL. and the Haemophilia Surveillance System Project Investigators. Prevalence and risk factors for heart disease among males with haemophilia. Am J Hematol 2005; 79: 36-42.
  • 13 Girolami A, Ruzzon E, Fabris F. et al. Myocardial infarction and other arterial occlusions in haemophilia A patients. A cardiologic evaluation of all 42 cases reported in the literature. Acta Haematologica 2006; 116: 120-125.
  • 14 Kingsley LA, Cuervo-Rojas J, Munoz A. et al. Sub-clinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. AIDS 2008; 22: 1589-1599.
  • 15 Curtiss LK. Clinical implications of basic research: Reversing atherosclerosis?. New Engl J Med 2009; 360: 1144-1146.
  • 16 Biere-Rafi S, Baarslag MA, Peters M. et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost 2011; 105: 274-278.
  • 17 Conroy RM, Pyörälä K, Fitgerald AP. et al, and the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.